A Th17-centered immune network for tertiary lymphoid structure formation in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy
Drug Resistance Updates · 2026-11 · 101502
DOI: 10.1016/j.drup.2026.101502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-11. Verfasst von Zihang Mai und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Die Arbeit nennt 87 Literaturangaben. Gefördert von: Medical Science and Technology Foundation of Guangdong Province, Sun Yat-Sen University Cancer Center, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
AIMS: Neoadjuvant immunochemotherapy (NICT) benefits esophageal squamous cell carcinoma (ESCC), yet underlying antitumor immunity remains elusive. This study aimed to dissect the cellular and molecular determinants and identify predictive biomarkers of NICT response in ESCC. METHODS: Longitudinal single-cell RNA and T/B cell receptor sequencing was performed on paired pre- and post-NICT ESCC samples from 20 patients. Spatial analyses and functional assays were employed to investigate the compartmentalized distribution and functional adaptation of cells within ESCC tumor microenvironment in response to NICT. RESULTS: Through single-cell multi-omics profiling of ESCC tumors, we identified Th17 accumulation accompanied by IL-22 and IL-17A upregulation in responders after NICT. IL-22 promoted differentiation of IL22RA1+ cancer-associated fibroblasts (CAFs) into CCL19+ CAFs and tertiary lymphoid structure (TLS) formation. Th17-derived IL-17A primed B cells differentiation toward the TNFSF9+ B trajectory with increased antibody production. Pretreatment quantification of IL22RA1⁺ fibroblasts predicted NICT response in ESCC. In mice, hydroxycholesterols or IL-17A and IL-22 supplementation induced TLS formation and improved immunochemotherapy efficacy. CONCLUSIONS: Our work delineates a Th17-CAF-B cell axis critical for TLS neogenesis and NICT response in ESCC, providing mechanism-based biomarkers for patient stratification and strategies to overcome treatment resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Thoracic Surgery, Sun Yat-sen Unive…
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
- Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
- Department of Thoracic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China.
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Förderung
- Medical Science and Technology Foundation of Guangdong Province
- Sun Yat-Sen University Cancer Center
- Guangdong Basic and Applied Basic Research Foundation
- Sun Yat-sen University State Key Laboratory of Oncology in South China
- National Natural Science Foundation of China
Zitieren
APA
Mai, Z., Wu, Q., Han, J., Wang, G., Li, Z., Yuan, J., Zhang, S., Lin, Q., Xie, X., Fu, J., Xie, X., & Wen, J. (2026). A Th17-centered immune network for tertiary lymphoid structure formation in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy. Drug Resistance Updates, 101502. https://doi.org/10.1016/j.drup.2026.101502
Vancouver
Mai Z, Wu Q, Han J, Wang G, Li Z, Yuan J, et al. A Th17-centered immune network for tertiary lymphoid structure formation in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy. Drug Resistance Updates. 2026:101502. doi:10.1016/j.drup.2026.101502
BibTeX
@article{Mai2026,
author = {Mai, Zihang and Wu, Qianlong and Han, Jingjing and Wang, Geng and Li, Zhenguo and Yuan, Jianye and Zhang, Shuyue and Lin, Qiuxia and Xie, Xiuying and Fu, Jianhua and Xie, Xuan and Wen, Jing},
title = {A Th17-centered immune network for tertiary lymphoid structure formation in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy},
journal = {Drug Resistance Updates},
year = {2026},
pages = {101502},
doi = {10.1016/j.drup.2026.101502}
}
EUVIMED